Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This is a single-arm, single-dose dose-escalation and dose-expansion study.

Trial Details

NCT ID
NCT06118788
Phase
PHASE1 / PHASE2
Sponsor
Guangzhou Bio-gene Technology Co., Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • BG1805
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Voluntarily sign the informed consent and be expected to complete the follow-up examination and treatment of the study procedures.
  • Age of 18-70 years old (inclusive of the cut-off value), regardless of gender.
  • Conforming to the diagnosis of AML according to the 2016 WHO classification, and conforming to the diagnostic criteria of relapsed and refractory a…
  • Relapsed AML diagnostic criteria: the reappearance of peripheral blood or bone marrow blasts after complete remission (CR); 5% (excluding other cau…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →